Correspondence  by unknown
a “dramatic proportion” of graft failure occurs soon after the
operation owing to “technical reasons.” In fact, we stated quite
clearly that the mean interval between CABG in our patients who
required redo CABG was 12.7 years. Therefore, there is good
reason to believe that atherosclerosis was present in our patients. If
C. pneumoniae is important in graft failure, patients with infection
would be expected to develop graft failure earlier. In a recently
published study, Bartels et al. (3) found results similar to ours in
that the interval between CABG was the same in patients with or
without infection.
Gurfinkel states that it is the immune response to infection that
is important and not the presence or absence of the organism in
atherosclerotic blood vessels, and although this may be true, there
is little supporting evidence. Also, the sentiment that the presence
of the organism in atherosclerotic vessels is evidence of its
involvement is widely held.
We agree that the interpretation of currently published antibi-
otic studies is problematic. The numbers of patients are too small
and the follow-up periods are too short. For example, Gurfinkel’s
own ROXIS (Randomized Trial of Roxithromycin in Non–Q-
wave Coronary Syndromes) secondary prevention trial was pub-
lished after 30 days of follow up with the thesis that antibiotics
reduced the incidence of adverse coronary events. However, results
after 180 days were no longer significant (4).
Currently, there is no conclusive evidence as to whether or not
C. pneumoniae causes atherosclerosis. That is why groups like ours
continue with research, because if it were responsible for only a small
proportion of cases, the influence on public health may be great.
Yuk-ki Wong, MD
Wessex Cardiothoracic Unit
Southampton General Hospital
Southampton, Hamphshire
United Kingdom
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Calculation Error in Study of Noninvasive
Index for Identifying Coronary Artery Disease
I would like to report errors in the recent article by Schmermund
et al. (1). The data found in the authors’ key table (Table 4.
Predictive Power of the Noninvasive Index) are flawed. The first
error involves the calculation of some of the sensitivities and
specificities reported in Table 4. With respect, I disagree with the
authors’ procedure: “A positive and negative test result was defined
as a value of the noninvasive index (NI) above or below specific Ta
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cutoffs.” (p. 446). In calculating sensitivity, we need to classify as
true positive results those with an NI score within or greater than
the category established as the cutoff score for a positive test result.
For example, all 68 of the patients with disease have at least a score
of category 3 (NI 4 to ,6). Thus, the sensitivity for category 3 is
100%. In calculating specificity, we need to classify as true negative
results those with an NI score lower than the category established
as the cutoff score for a positive test result. For example, all 223 of
the patients without disease have an NI score of category 1 or
greater. Because an NI score of 0 is within category 1, it is logical
that the specificity for category 1 would be 0%. There are no true
negative results for category 1. I have corrected the sensitivities and
specificities in Table 4 as required.
Because the authors’ sensitivities were often incorrect, their
positive likelihood ratios and negative likelihood ratios are also
flawed. In addition, the authors erred in the formula used for the
negative likelihood ratio. On page 446, the authors give the
formulas for the positive likelihood ratio and the negative likeli-
hood ratio. This latter formula is incorrect. The negative likelihood
ratio is a false negative rate divided by a true negative rate, or 1 2
sensitivity/specificity. The authors’ mistake was to invert the
numerator and denominator.
Using inaccurate sensitivities and specificities and a flawed
formula for the negative likelihood ratio, the authors’ Table 4
reports incorrect calculations for their post-test probabilities. In my
redone Table 4, I also report the correct post-test probabilities. I
hope these correctly calculated sensitivities and specificities, like-
lihood ratios and post-test probabilities will be helpful to your
readers as they assess the value of this otherwise well-conducted
study for their clinical practice.
Ronald J. Markert, PHD
Professor of Internal Medicine
Wright State University School of Medicine
Dayton, Ohio
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REPLY
We thank Dr. Markert for his interest in our work, but would like
to point out that there are no errors in the table or flawed data. The
noninvasive index categories defined in Table 4 of our article
comprise patients with and without angiographic three-vessel
and/or left main coronary artery disease, as explained in the table.
Regarding calculations of sensitivities and specificities, we did not
specify in the Methods section or Table 4 what was done with the
interval itself (the specific row category), and we apologize for any
confusion this may have caused. In fact, we always included the
row in question in the lower category, thus using the “upper” limit
of the category as the test threshold value. Dr. Markert would have
preferred our using the “lower” limit of the category, but this is
only a nonsubstantial difference in the presentation of the data.
The likelihood ratios, as presented in our study, are correct. In
particular, the formula for the negative likelihood ratio given in our
report, as well as the way in which it was used, is correct. This is
intuitively apparent when one considers that the formula suggested
by Dr. Markert, using the inverse of our ratio, yields a posttest
probability of disease and a posttest probability of no disease, both
increasing in the same direction. We used the formulas presented
in the Methods section of our article in a consistent fashion,
seeking to express the strength with which a positive or negative
test result reinforced a positive or negative conclusion, respectively.
The posttest probability of no disease was calculated on the basis
of a negative test result (value below cutoff). The author of
reference 27 cited in our study has seen and verified our version of
this formula.
Axel Schmermund, MD
Department of Cardiology
University Clinic Essen
Essen, Germany
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Enhanced Activity of Sodium–Lithium
Countertransport in Patients With Cardiac
Syndrome X: A Potential Link Between
Cardiac and Metabolic Syndrome X
We read with interest the article by Gaspardone et al. (1) detailing
their work with cardiac patients with syndrome X. These authors
have shown the clearest separation in sodium–lithium counter-
transport (SLC) activity between patients and healthy control
subjects since activity was first described by Canessa et al. (2) in
1980, who showed a clear difference between hypertensive patients
and normotensive volunteers. The possibility of using SLC activity
as a marker for predisposition to hypertension and for differenti-
ation between primary and secondary forms of the disease naturally
followed (3). However, subsequent studies were unable to repro-
duce the clear separation (4). It was eventually realized that the
overlap of activity values between healthy and hypertensive subjects
restricted the value of SLC as a prognostic test. In later years, it
emerged that the patients in the 1980 study represented some of
the most severely affected patients attending the hypertension
clinic in Boston at that time (Dr. Canessa, personal communica-
tion, Boston, Massachusetts, 1991). Nevertheless, study of SLC
raised interesting questions as to how a defect in a cell membrane
transporter could relate to the development of hypertension.
In the mid 1980s, focus shifted from SLC as a marker of
hypertension to the associations between behavior of this trans-
porter and metabolic disorders. It is now generally accepted that
expression of SLC is in some way linked to insulin resistance,
vascular disease and diabetes (5). However, until now, no clear
differentiation has been shown between SLC activity in health and
that in disease, and no specific pathophysiologic link between SLC
and vascular disease has been reported. In making this observation
in such a specific group of patients, Gaspardone et al. (1) bring us
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